Company intelligence / Profile preview

CanariaBio

Ownership: Private
Development stage: Phase 3

Overview

CanariaBio has completed enrollment for a Phase II ovarian cancer trial as of August 2024. Their lead product oregovomab is in Phase III trials for ovarian cancer treatment across 163 sites in 16 countries. The company is also developing other immunotherapies for cancer indications with high unmet medical needs.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesImmunotherapiesSmall molecule drugs
Industry: Biotech

Drug pipeline

1 asset

AR20.5

Preclinical

Partnerships

Hikma

Beyond the preview

Go deeper on CanariaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanariaBio.

Explore the full profile